Measuring HIV-related mortality in the first decade of anti-retroviral therapy in sub-Saharan Africa. by Todd, Jim et al.
Todd, J; Slaymaker, E; Zaba, B; Mahy, M; Byass, P (2014) Measuring
HIV-related mortality in the first decade of anti-retroviral therapy in
sub-Saharan Africa. Global health action, 7. p. 24787. ISSN 1654-
9716 DOI: 10.3402/gha.v7.24787
Downloaded from: http://researchonline.lshtm.ac.uk/1775868/
DOI: 10.3402/gha.v7.24787
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
MEASURING HIV ASSOCIATED MORTALITY IN AFRICA
EDITORIAL
Measuring HIV-related mortality in the first decade of
anti-retroviral therapy in sub-Saharan Africa
This paper is part of the Special Issue: Measuring HIVAssociated Mortality in Africa. More papers from this
issue can be found at http://www.globalhealthaction.net
F
or the past 30 years, many communities and
countries in sub-Saharan Africa have suffered from
the ravages of the HIV epidemic. During this time
the mortality rates in HIV-infected people have been 10
20 times higher than in HIV-uninfected people (1). Since
the advent of anti-retroviral therapy (ART), mortality
and morbidity have decreased considerably (2). However,
it has been difficult to get reliable estimates of the impact
of ART in population-based studies. The measurement
of the impact of ART on mortality requires long-term
follow-up in communities where regular HIV testing
allows the estimation of mortality by HIV status, such as
the population cohorts in the network for Analysing Lon-
gitudinal Population-based HIV data in Africa (ALPHA)
(3). An alternative estimation from verbal autopsy (VA)
requires reliable tools and consistent interpretation of
causes of death, which have been taken forward by
recent standards from the World Health Organization
(WHO) and the development of the corresponding
InterVA-4 model for cause of death assignment (4, 5).
This supplement puts together evidence from different
sources in order to estimate the impact of ART on adult
HIVmortality. The papers in this supplement use different
measures to estimate the effect of ART, and the stories
from the different papers provide a consistent picture of
the reduction in HIV-related mortality with the advent of
ART in sub-Saharan Africa. However, in developed
countries the mortality in HIV-positive people on ART
is similar to the mortality in the general population (6),
but based on the evidence from the population studies
reported in this supplement, it is not the case in sub-
Saharan Africa, even if it may be achieved in the future.
The AIDS impact module within the Spectrum soft-
ware is a modeling tool for estimating many facets of the
HIV epidemic in the population, usually using HIV
prevalence and program data available at the national
level (7). We can evaluate the mortality estimate from the
Spectrum model against the empirical data from long-
itudinal studies if we can accurately create a Spectrum
model for the small area where the longitudinal study is
located. This comparison allows us to validate the
assumptions used in Spectrum that lead to the mortality
estimates from the model.
The paper by Kanjala et al. documents the changes in
age-specific mortality rates (ASMR) from 1994 to 2010 in
a cohort in Tanzania (8). This study showed an overall
reduction in mortality in those aged 1559 from 12.3 per
1,000 person years (95% CI 11.513.1) in the 5 years
before ARTwas introduced to 8.0 per 1,000 person years
(95% CI 7.28.8) after ART was introduced. In that
period, the greatest reduction was seen in HIV positives
aged 3045 years, with a 44% reduction in male
mortality, and a 71% reduction in female mortality in
this group. For both sexes, the HIV-attributable mortality
among the population showed a reduction from more
than 50% in 2000, to around 35% in 2010, which can be
related to the availability of ART since around 2005. The
pooled analysis of adults aged 1554 in five sites in East
and Southern Africa showed an overall halving of the
excess mortality in HIV positives, with the decline evident
across all sites and for both sexes (9).
Four papers in this supplement reported the use of
InterVA-4 to interpret the cause of death from VA data.
Byass et al. validated the InterVA-4 model against pre-
mortem serological data from six ALPHA sites (5). This
showed 90% specificity in identifying HIV-related deaths
among those with confirmed HIV sero-status, which
was consistent across the six sites, and across time,
making InterVA-4 an effective tool in assessing HIV-
related mortality. Glynn et al. compared the use of
InterVA-4 with the interpretation of deaths by clinician
review in Malawi from 2002 to 2012 (10). The results
confirm the specificity of InterVA-4, as 88% of the deaths
identified as unrelated to HIV by the physicians were
correctly identified by InterVA-4. For HIV-related deaths
defined by the physician review, InterVA-4 identified 59%
due to HIV/AIDS, and a further 20% where TB was the
cause of death. Byass et al. identified these two causes
(HIV/AIDS and TB) plus acute respiratory infections as
highly associated with HIV positivity, indicating that
these are likely causes of death in people living with HIV
(5). Both Glynn and Kanjala reported that InterVA-4
may underestimate the number of deaths due to HIV,
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perhaps through coding of such deaths under different
causes (8, 10). This raises questions about the ICD-10
coding rules whereby almost all deaths among HIV
positives are expected to be coded as HIV related (11).
This is likely to become a bigger issue as more HIV-
positive individuals experience ART for longer periods of
time, before going on to die from a potentially wider
range of causes.
Two papers used Spectrum model estimates and
showed good agreement with empirical data in Kenya
and Tanzania (12, 13). Oti et al. compared the Spectrum
model outputs for the Nairobi area against the health and
demographic surveillance site (HDSS) observed mortality
using InterVA-4 to interpret cause of death. The Spec-
trum model estimated that in 2003, 63% of adult
mortality was HIV-related, decreasing to 40% in 2010,
while for InterVA-4, including deaths from both HIV/
AIDS and TB showed that 59% were HIV-related in
2003, and 46% in 2010. In Tanzania, using adult
mortality between the ages of 15 and 49 years, Michael
et al. found the Spectrum model estimated that HIV-
related mortality had fallen from 43% in 1994 to 37% in
2009, compared to the results from the demographic and
serological data which showed a reduction from 39 to
22% over the same period. They concluded that Spectrum
predicts a greater proportion of adult deaths being due to
HIV than observed in the cohort, and speculate that this
may have been influenced by the low reported uptake of
ART services in the cohort. Further work is needed to
refine the Spectrum models created using small area data
(as opposed to national data which is usually used for
Spectrum estimates), but this seems a useful challenge to
bring together the Spectrum model with existing HDSS
data, and to identify the limitations of such comparisons.
Most countries have now adopted the 2010 WHO
guidelines to initiate ART for those with HIV infection
and CD4 counts under 350 cells per mm3, but new
guidelines in 2013 recommend initiation of ART in all
those with CD4 counts less than 500 cells per mm3 (14).
Masiira et al. used standardized mortality rates (SMR)
for HIV-positive, ART-naive Ugandan adults, and com-
pared the mortality of those with CD4 counts between
350 and 499 cells per mm3, to those with CD4 counts
greater than 500 cells per mm3, and with the Ugandan
general population (15). Mortality rates were 1.6 times
higher in those with lower CD4 counts (between 350 and
499 cells per mm3), and 2.5 times higher than the general
population. The excess HIV mortality in those with CD4
counts between 350 and 499 cells per mm3 would be
prevented with the implementation of the WHO guide-
lines for people living with HIV in developing countries.
The final paper in the supplement, by Levira et al.,
looks at a different impact that ART may have on
mortality (16). Many people migrate back from the cities
to their rural home villages when severely sick and
expecting to die (17). With the advent of ART, the
mortality among urbanrural migrants in Tanzania has
reduced by 39% compared to a reduction of 27% among
non-migrants.
The message from the papers in this supplement across
the first decade of ART roll-out in sub-Saharan Africa
shows a consistent reduction of overall mortality rates in
the population of around 30%, with the proportion of
deaths attributable to HIV falling by 3050%. In this
period, excess mortality among HIV-positive adults has
halved, but the mortality rates in HIV positives are still
up to 10 times higher than among HIV negatives (9). In
the coming decade, there is a lot more to be done in terms
of increasing access to, and availability of, ART. This
should lead to further reductions in mortality rates, but
will also bring new challenges to measuring HIV-related
mortality, particularly among those who have received
long-term treatment.
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